Meeting Report

New Treatment Paradigms Defined for Chronic Lymphocytic Leukemia

Presented by Mollie Moran, CNP, and Jeffrey Jones, MD, MPH

The James Cancer Hospital at The Ohio State University, Columbus, Ohio

Presenters’ disclosures of potential conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2017;8:273–278 | https://doi.org/10.6004/jadpro.2017.8.3.10 | © 2017 Harborside Press®


  

ABSTRACT

Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, there is a need for advanced practitioners to stay up to date and informed in order to translate these advances into the clinical setting.


For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here